Whatman Anotop sterile syringe filters from Cytiva contain an inorganic Anopore membrane. The low protein binding exhibited by this sterile membrane filter make it well suited for biological filtration.
Whatman Anotop sterile syringe filters from Cytiva contain an inorganic Anopore membrane. The low protein binding exhibited by this sterile membrane filter make it well suited for biological filtration.
Sterile syringe filters for critical applications
Aluminum-based inorganic Anotop syringe filters in three pore sizes
Compatible with most organic solvents and aqueous samples
Low hold-up volume (< 20 μL for Anotop 10) for maximum sample recovery
Made without wetting agents or adhesives for low risk of sample contamination
Whatman Anotop filters offer chemical inertness and functionality in a wide range of solvents and temperatures. Sterile Anotop filters can be used as a phage and virus filtration membrane, or for cold sterilization* of growth media, protein removal, filtration prior to spectrophotometric analysis, or other analytical methods.
Low protein binding polypropylene syringe filters
Unlike many organic membranes, the inorganic Anopore membranes in Anotop syringe filters have sharply defined capillary pore structures with narrow pore-size distribution.
The syringe filter’s pigment-free polypropylene housing is made without wetting agents or adhesives, designed for low extractable levels, low protein binding, and minimal sample hold-up. These features make Anotop syringe filters a good option for filtration of valuable, proteinaceous samples where minimal loss is required.
Looking for a filter paper, membrane filter, or syringe filter Let Cytiva help you find the optimal filter for your needs to ensure reliable analysis.
*Refers to sterilization by filtration for small sample use which is an industry term for filters of pore size 0.2 um or smaller as referenced in guidance such as EPA Guidance for Industry Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice Section IX, Part B (September 2004).
